CERA

unofficial impact factor 1.46
Search for
Advanced search
Cost Effectiveness and Resource Allocation
Tools
Open Access Highly Access Email this article to a friend

Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective

Werner A Scherbaum, Gordon Goodall, Katrina M Erny-Albrecht, Massimo Massi-Benedetti, Erland Erdmann and William J Valentine*

Cost Effectiveness and Resource Allocation 2009, 7:9 doi:10.1186/1478-7547-7-9

Fields marked * are required


Multiple email addresses should be separated with commas or semicolons.